Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide plus low-dose dexamethasone continuation study in relapsed/refractory multiple myeloma after MK-3475-183 termination
MOH_2017-12-05_001998Phase 3Not yet recruiting
- Sponsor
- ד"ר נעם בנימיני
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by ד"ר נעם בנימיני. Primary endpoint: Progression-free survival. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
pomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2017-12-05_001998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-05_001998.